DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Posted by Doug Wharley on May 7th, 2024

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a report released on Monday morning. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $10.00 price target on shares of DBV Technologies in a research report on Wednesday, February 21st.

Check Out Our Latest Stock Report on DBVT

DBV Technologies Price Performance

DBVT opened at $0.67 on Monday. DBV Technologies has a 52-week low of $0.65 and a 52-week high of $2.37. The business’s fifty day moving average is $0.75 and its 200-day moving average is $0.84.

DBV Technologies (NASDAQ:DBVT – Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. The firm had revenue of $8.88 million for the quarter, compared to the consensus estimate of $1.10 million. During the same period in the prior year, the company posted ($0.23) earnings per share. On average, research analysts expect that DBV Technologies will post -0.88 earnings per share for the current year.

Institutional Trading of DBV Technologies

Large investors have recently bought and sold shares of the business. Optiver Holding B.V. lifted its holdings in shares of DBV Technologies by 595.2% in the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after acquiring an additional 235,337 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in shares of DBV Technologies during the 3rd quarter valued at approximately $94,000. Finally, Cowen AND Company LLC acquired a new position in DBV Technologies during the 4th quarter worth approximately $49,000. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.